Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP2 + durvalumab
- Development stage
- Unknown
- Lead developer
- Replimune
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
RP2 + durvalumab is an investigational combination therapy consisting of RP2, an oncolytic herpes simplex virus type 1 (HSV-1) engineered to express a fusogenic glycoprotein and the immune co-stimulator GM-CSF, combined with durvalumab, a human monoclonal antibody targeting PD-L1. RP2 is designed to selectively replicate in and lyse tumor cells, promoting immunogenic cell death and recruiting immune cells to the tumor microenvironment, while durvalumab blocks PD-L1–mediated immune evasion, thereby enhancing antitumor immune response. This combination aims to synergize direct tumor cell killing with checkpoint blockade immunotherapy to improve clinical outcomes in solid tumors.
- Brand names
- Imfinzi
- Other names
- RP2 + ImfinziRP2 in combination with durvalumabRP-2 in combination with durvalumabRP 2 in combination with durvalumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on RP2 + durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP2 + durvalumab.